Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Date:11/9/2007

Interim analysis of Phase 2 clinical data presented at the 2007

Chemotherapy Foundation Symposium

BOULDER, Colo., Nov. 9 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today released interim findings from its Phase 2 trial of Amrubicin in second-line chemo-sensitive small cell lung cancer (SCLC). Amrubicin, the company's third-generation synthetic anthracycline, is a potent topoisomerase II inhibitor currently in development for the treatment of SCLC. These findings indicate favorable interim results in terms of response rate and survival for Amrubicin in second-line treatment of small-cell lung cancer patients with extensive disease (ED) SCLC. The early results of this study were presented at the 2007 Chemotherapy Foundation Symposium today in New York City.

"Treatment options for second-line SCLC are limited and preliminary data from the US-based Phase 2 sensitive SCLC trial indicate that Amrubicin may provide a new option for SCLC patients who desperately need more treatment choices," said principal investigator Robert M. Jotte, MD, PhD, Medical Director of the Lung Cancer Clinic of the Rockies, Developmental Co-Chair USON Lung Committee. "As we near completion of the Phase 2 trial, we hope that accrual to the Phase 3 trial will be rapid and confirm the results of the US Phase 2 trial and similar trials in Japan."

The trial presented today compares Amrubicin and topotecan in patients with ED-SCLC that initially responded to first-line platinum-based therapy but whose disease recurred or progressed at least 90 days after completion of first-line treatment (sensitive SCLC). Study participants are randomized in a 2:1 ratio to receive either IV Amrubicin (40mg/
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
6. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
7. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
8. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
9. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
10. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
11. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Kan. , July 25, 2014 /PRNewswire-iReach/ -- ... and TCGRx, of Powers Lake, Wisconsin ... partners in a distribution and co-marketing agreement allowing ... retail pharmacies throughout the United States ... robotics-based pharmacy management and workflow systems to retail ...
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation (NYSE: ... call on Tuesday, August 5, 2014, at 8:30 a.m. ... quarter 2014 financial results. An audio webcast ... the Investor Relations portion of the CVS Caremark website ... http://info.cvscaremark.com/investors . This webcast will be archived and ...
(Date:7/25/2014)... Trinidad and Tobago , July 25, 2014 ... the Trinidad & Tobago Ministry of Health approved ... therapy that significantly increases the cure rate from ... infected with the genotype 1 virus. Telaprevir is ... the trade brand INCIVO®. Photo - ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... The University of Oxford Clinical Trial,Service Unit ... results of the SEAS trial of ezetimibe should ... the SHARP and,IMPROVE-IT trials of ezetimibe, and reporting ... independently of the drug,manufacturers., The two hypothesis-testing ...
... clinicians identify risk in patients, including ... BIRMINGHAM, Ala., July 21 Using the ... link between,adiponectin and heart disease progression. The information ... cholesterol and heart,disease risk-lowering treatments in at-risk patients., ...
Cached Medicine Technology:Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 3VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 2VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 3
(Date:7/25/2014)... (HealthDay News) -- Shift workers, especially men, may be at ... on such schedules, a new study suggests. Also at ... set schedule, with shifts moving around at various times of ... said one expert, Dr. Alan Manevitz, a clinical psychiatrist at ... long known that working shifts disrupts many key body chemicals, ...
(Date:7/25/2014)... The American Society of Anesthesiologists (ASA) today announced ... (PSH) Learning Collaborative, a national initiative designed to ... surgery. More than 40 leading health care ... the collaborative, which will convene for the first ... July 25-26, in Schaumburg, Ill. , The PSH ...
(Date:7/25/2014)... 25, 2014 In today’s technological era, ... and supporting devices. This benefits the organization in various ... cyber attacks which can destroy the confidential information and ... Risk and Compliance (EGRC) manage and protect the enterprise ... can cause loss in dollars to the comp may. ...
(Date:7/25/2014)... Dallas, TX (PRWEB) July 25, 2014 ... Market Outlook to 2020” provides company shares and ... categories, and global corporate-level profiles of the key ... related to the Laryngoscopes market wherever available. , ... dynamic market forecast models. Rsearcher uses epidemiology and ...
(Date:7/25/2014)... A protein that controls when genes are switched on ... of the brain to regulate metabolism, UT Southwestern Medical ... to new therapies to treat obesity and diabetes, since ... 1 (Xbp1s) appears to influence the body,s sensitivity ... hormones central to the body,s regulation of food intake ...
Breaking Medicine News(10 mins):Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2
... for Seven Water Bodies; New Species, Water Body Added , ... fish consumption advisories that include two new fish species and ... list, but also eases or lifts advisories on fish from ... an interagency partnership between the Pennsylvania Fish and Boat Commission ...
... ... to serve more effectively millions of people suffering from alcohol abuse worldwide.....read more... ... ... has completely redesigned its website to serve more effectively millions of people suffering ...
... ... its highly acclaimed Restore® program, which provides immediate support and practical advice to family ... ... Alcohol Recovery (NIFAR®) is introducing a new version of its highly acclaimed Restore® ...
... sooner, with no fasting, , TUESDAY, Dec. 29 (HealthDay News) ... Diabetes Association is promoting a more prominent role for the ... diabetes and prediabetes. , Long used in the management of ... for the previous two to three months. The new guidelines ...
... , Health gurus say recommit each Monday until the habit ... January 1st millions of Americans will resolve to quit smoking -- again. ... Johns Hopkins and the American Cancer Society say it doesn,t have to ... agree, just quit again the following Monday. And recommit to stay quit ...
... 29 Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), ... a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system ... today provided a business update, and management reiterated its ... Echo completes the development and regulatory review of its ...
Cached Medicine News:Health News:Updated Fish Consumption Advisories Issued for 2010 2Health News:Updated Fish Consumption Advisories Issued for 2010 3Health News:New NIFAR Website Offers Millions a Comprehensive Resource for Alcohol Education, Recovery, and Support 2Health News:New NIFAR Website Offers Millions a Comprehensive Resource for Alcohol Education, Recovery, and Support 3Health News:Innovative Program Gives Instant Support to Millions who are Living and Suffering with a Problem Drinker 2Health News:Innovative Program Gives Instant Support to Millions who are Living and Suffering with a Problem Drinker 3Health News:New Guidelines Urge A1C Test for Diabetes Diagnosis 2Health News:This New Years, Smokers Get 52 Chances to Stay Quit 2Health News:Echo Therapeutics Provides Business Update 2Health News:Echo Therapeutics Provides Business Update 3Health News:Echo Therapeutics Provides Business Update 4Health News:Echo Therapeutics Provides Business Update 5
... Mapping. Biosense Webster offers a complete ... SANTORO Fixed Catheter is designed for ... the coronary sinus. The pair of ... tip permit pacing in the coronary ...
Standard Deflectable Catheters...
... Soft HIS diagnostic catheters provide ... designed curve that allows for ... HIS bundle. In addition, the ... reduce the risk of perforation ...
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures....
Medicine Products: